Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of response to interferon therapy.
Gogas H, Kirkwood JM. Gogas H, et al. Curr Opin Oncol. 2009 Mar;21(2):138-43. doi: 10.1097/CCO.0b013e328325317a. Curr Opin Oncol. 2009. PMID: 19532015 Review.
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Gogas H, et al. N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007. N Engl J Med. 2006. PMID: 16481638 Free article. Clinical Trial.
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: gogas h. Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial.
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H. Pectasides D, et al. Among authors: gogas h. J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139440 Clinical Trial.
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Gogas H, et al. J Transl Med. 2010 Nov 3;8:108. doi: 10.1186/1479-5876-8-108. J Transl Med. 2010. PMID: 21044351 Free PMC article.
New challenges in endpoints for drug development in advanced melanoma.
Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. Ribas A, et al. Among authors: gogas h. Clin Cancer Res. 2012 Jan 15;18(2):336-41. doi: 10.1158/1078-0432.CCR-11-2323. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142824 Free PMC article.
329 results